IgA nephropathy remains the most common immune-mediated glomerular disease worldwide — and up to 50% of patients may progress to kidney failure within a decade. 🧬
The 2025 KDIGO guidance emphasizes early biopsy (proteinuria ≥0.5 g/day), tight BP control (<120/70), renin-angiotensin system inhibition, SGLT2 inhibitors, and targeted therapies such as budesonide and complement inhibition.
Proteinuria remains the key modifiable driver. Precision nephrology is here — and measurable. 🩺📉
